1-5 of 5
Beth Overmoyer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

Tanya E. Keenan, Tianyu Li, Tuulia Vallius, Jennifer L. Guerriero, Nabihah Tayob, Bose Kochupurakkal, Janae Davis, Ricardo Pastorello, Rie K. Tahara, Leilani Anderson, Jake Conway, Meng X. He, Erin Shannon, Robert E. Godin, Peter K. Sorger, Alan D'Andrea, Beth Overmoyer, Eric P. Winer, Elizabeth A. Mittendorf, Eliezer M. Van Allen, Geoffrey I. Shapiro, Sara M. Tolaney
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (4): 983–991.
https://doi.org/10.1158/1078-0432.CCR-20-3089
Published: 15 February 2021
View article titled, Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer
Open the PDF for Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers

Joseph Baar, Paula Silverman, Janice Lyons, Pingfu Fu, Fadi Abdul-Karim, Nicholas Ziats, Jay Wasman, Paul Hartman, John Jesberger, Leda Dumadag, Erin Hohler, Rosemary Leeming, Robert Shenk, Helen Chen, Keith McCrae, Afshin Dowlati, Scot C. Remick, Beth Overmoyer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3583–3590.
https://doi.org/10.1158/1078-0432.CCR-08-2917
Published: 18 May 2009
View article titled, A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers
Open the PDF for A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers in another window
Journal Articles

Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin

Beth Overmoyer, Pingfu Fu, Charles Hoppel, Tomas Radivoyevitch, Robert Shenk, Marjie Persons, Paula Silverman, Kelly Robertson, Nicholas P. Ziats, Jay K. Wasman, Fadi W. Abdul-Karim, John A. Jesberger, Jeffrey Duerk, Paul Hartman, Shelli Hanks, Jonathan Lewin, Afshin Dowlati, Keith McCrae, Percy Ivy, Scot C. Remick
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5862–5868.
https://doi.org/10.1158/1078-0432.CCR-07-0688
Published: 01 October 2007
View article titled, Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin
Open the PDF for Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin in another window
Journal Articles

Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer

Matthew M. Cooney, Tomas Radivoyevitch, Afshin Dowlati, Beth Overmoyer, Nathan Levitan, Kelly Robertson, Sandra L. Levine, Kathleen DeCaro, Carol Buchter, Anne Taylor, Bruce S. Stambler, Scot C. Remick
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 96–100.
https://doi.org/10.1158/1078-0432.CCR-0364-3
Published: 20 January 2004
View article titled, Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer
Open the PDF for Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer in another window
Journal Articles

Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel

Deborah Toppmeyer, Andrew D. Seidman, Michael Pollak, Christy Russell, Katherine Tkaczuk, Shailendra Verma, Beth Overmoyer, Varun Garg, Ene Ette, Matthew W. Harding, George D. Demetri
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (3): 670–678.
Published: 01 March 2002
View article titled, Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel
Open the PDF for Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel in another window